11月12日下午，中科院成都信息技术股份有限公司（以下简称"公司"）在公司会议室接待了机构及个人 投资者的现场参观调研。本次调研参与机构包括浙商证券、光华上智、昱奕资产、浙商银行、海子基 金、旷谷投资等6家，另有多位个人投资者参与。公司董事会秘书刘小兵、董事会办公室主任兼证券事 务代表吴琳琳就公司核心技术、业务进展、业绩预期及战略规划等核心问题与投资者进行了深入交流。 谈及核心业务定位，公司指出，现有业务覆盖人工智能、机器人、数字经济、机器视觉、信创、医疗等 多个领域，其中最核心的板块为人工智能、机器视觉及信创。 调研中，机构首先关注公司高速机器视觉技术的核心竞争力。公司方面解释，高速机器视觉与传统机器 视觉的关键区别在于，能否在保证检测高精度的前提下，实现检测速度高于设备生产运行速度，并处理 大批量数据。其技术优势集中在大批量连续制造生产场景，可实时完成产品缺陷检测、大规模数据采集 分析及人机交互，实现残次品精准剔除。 新签订单创新高 信创业务贡献3.3亿订单 针对业绩表现，公司表示，去年及今年前三季度业绩暂未达预期，主要受两方面因素影响：一是各行业 客户项目实施周期不同，部分项目尚未完成验收确认营业收入； ...

投资者关系活动记录表 编号：2025-13 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 □ 业绩说明会 | | □ | 新闻发布会 路演活动 □ | | √ | 现场参观 | | □ | 其他 （） | | 参与单位名称及 | 浙商证券：孙二召、陈 攀、洪 皓、吴 彪、陈 彦、匡晓雪、 | | 人员姓名 | 吴 剑、杨 旭、张金花、李 玲 | | | 光华上智：陈永生 昱奕资产：温相波 浙商银行：梁 雪 | | | 海子基金：陈海林 旷谷投资：杨永芳 | | | 个人投资者：刘 建、帅 丽、谢 斌、李 根、冯 伟、赵怀刚、 | | | 郑 雁、陈 宇、杨治国 | | 时间 | 年 月 日 （星期三）下午 2025 11 12 15:30~17:30 | | 地点 | 公司会议室 | | 上市公司接待人 | 董事会秘书刘小兵、董事会办公室主任兼证券事务代表吴琳琳 | | 员姓名 | | | | 一、参观公司品牌体验馆，了解技术与业务； | | | 二、交流座谈 | | | 1. 公司高速机器视觉与机器视觉的区别是什么? | | | 答：高速 ...

Summary of Key Points Core Viewpoint - The financing balance of the ChiNext market has decreased, with a total of 527.88 billion yuan, reflecting a reduction of 16.13 billion yuan from the previous trading day, while 17 stocks saw an increase in financing balance of over 10% [1][2]. Financing Balance Overview - The latest financing balance for ChiNext stocks is 526.03 billion yuan, down by 16.26 billion yuan compared to the previous day [1]. - The margin trading balance for ChiNext stocks is 527.88 billion yuan, with a decrease of 16.13 billion yuan from the previous trading day [1]. Stocks with Increased Financing Balance - A total of 462 stocks experienced an increase in financing balance, with 17 stocks showing an increase of over 10% [1]. - The stock with the highest increase in financing balance is Zhongfu Circuit (300814), which saw a financing balance of 673.41 million yuan, an increase of 46.83%, and its stock price rose by 9.95% [3]. - Other notable stocks with significant increases include Baicheng Pharmaceutical (301096) and Boying Special Welding (301468), with increases of 27.52% and 24.85%, respectively [1][3]. Stocks with Decreased Financing Balance - A total of 484 stocks saw a decrease in financing balance, with 51 stocks experiencing a decline of over 5% [3]. - The stock with the largest decrease is Jundingda (301538), with a financing balance of 159.16 million yuan, down by 21.42% [4]. - Other stocks with significant declines include Xice Testing (301306) and Huaxing Chuangye (300025), with decreases of 19.55% and 19.11%, respectively [4]. Market Performance - Among the stocks with increased financing balance, the average increase in stock price was 1.85%, with 13 stocks rising [2]. - The stocks with the highest price increases include Zhongfu Circuit, Kexiang Co. (300903), and Dongya Machinery (301028), with increases of 9.95%, 9.05%, and 6.49%, respectively [2]. - Conversely, Baicheng Pharmaceutical, Haili Wind Power (301155), and Boying Special Welding experienced the largest declines, with decreases of 10.78%, 7.51%, and 6.52%, respectively [2]. Capital Flow - On November 4, 13 stocks with increased financing balance saw net inflows of main funds, with Kexiang Co., Zhongke Information (300678), and Boke New Materials (300811) leading with net inflows of 116 million yuan, 108 million yuan, and 79.31 million yuan, respectively [2]. - Conversely, four stocks experienced net outflows, with Baicheng Pharmaceutical, Xingyuan Zhuomei (301398), and Zhiyuan New Energy (300985) seeing the largest outflows of 326 million yuan, 3.51 million yuan, and 2.77 million yuan, respectively [2].

Core Insights - The National Health Commission released implementation opinions to promote and regulate the application of "Artificial Intelligence + Healthcare," outlining eight key application areas and development goals for 2027 and 2030 [1][2]. Group 1: Key Application Areas - The eight key areas identified include AI + grassroots applications, AI + clinical diagnosis, AI + patient services, AI + traditional Chinese medicine, AI + public health, AI + research and education, AI + industry governance, and AI + health industry [2][3]. - The focus on grassroots applications aims to enhance intelligent services in areas such as medical imaging, ECG diagnosis, and public health management [3]. Group 2: Development Goals - By 2027, the goal is to establish high-quality health data sets and intelligent applications in clinical settings, with a focus on major diseases and enhancing diagnostic capabilities [2][4]. - By 2030, the aim is for intelligent applications in grassroots diagnosis to achieve full coverage, with advanced AI applications in secondary and tertiary hospitals [2]. Group 3: Company Opportunities - A-share companies like Shanhai Mountain, Yunnan Baiyao, and Aojiahua have already made early investments in AI + healthcare, positioning themselves to benefit from the policy's support [1][4]. - Companies such as Keda Xunfei and Yunkang Life are developing AI solutions for imaging and comprehensive healthcare services, enhancing patient experience and operational efficiency [4][5]. Group 4: Focus on Medical Robots - The implementation opinions emphasize the promotion of intelligent medical devices, including rehabilitation and acupuncture robots, indicating a growing market for AI-driven medical equipment [5]. - Companies like Aojiahua are developing smart massage robots based on traditional Chinese medicine principles, showcasing innovation in the sector [5]. Group 5: Patient Services and Research - The implementation opinions highlight the need for AI to enhance patient services, including intelligent appointment scheduling and pre-consultation services in hospitals [5][6]. - Companies like Yunnan Baiyao are advancing drug research through AI systems that predict the effects of new molecules, indicating a trend towards integrating AI in pharmaceutical research [6].

Group 1: Company Performance - The company achieved a new high in new contract signing, with a growth of 282.6% in 2025 [2][3] - Despite the increase in new contracts, revenue and profit showed a year-on-year decline due to the timing of contract signing and project implementation cycles [3][4] - The company has confidence in revenue recognition by year-end and next year's performance as projects progress [3] Group 2: Business Lines and Core Competencies - The company has diversified into multiple business lines, supported by a history of research and development in various fields [4] - Core competencies are built around high-speed machine vision technology, serving industries such as tobacco, oil and gas, and printing [4] - The current business segments include smart governance, intelligent manufacturing, smart cities, and smart healthcare [4] Group 3: Future Directions and Innovations - The company plans to focus on the development of domestic alternatives in line with national industrial policies [5][6] - In the smart healthcare sector, the company promotes intelligent anesthesia robots, which assist but do not replace doctors [7] - The company is actively developing a digital meeting system and low-code development platforms, enhancing its capabilities in the smart governance sector [6] Group 4: Financial Management and Challenges - The increase in accounts receivable is manageable, primarily due to the nature of large engineering projects and the funding cycles of government and large enterprises [8] - The company maintains a low percentage of receivables over five years, indicating controlled risk [8] Group 5: Market Impact and Adaptation - The digitalization of currency is seen as a complement to physical currency, with no significant impact on the company's printing business [9] - The demand for physical currency is expected to rise due to the internationalization of the RMB and the "Belt and Road" initiative [9] Group 6: Product Development and Technology - The company is developing intelligent agents to enhance its low-code development platform, improving efficiency in data querying and software testing [10] - Approximately 330 million RMB in new orders are attributed to the domestic alternative business, with growth in existing industry sectors contributing to overall performance [10][11]

Core Insights - Zhongke Information, established in 2001 and listed in 2017, is a leading provider of AI-based industry information solutions in China, focusing on high-speed machine vision and big data technologies [1] Financial Performance - For Q3 2025, Zhongke Information reported revenue of 194 million yuan, ranking 106th among 131 companies in the industry, significantly lower than the top company, Digital China, with 102.365 billion yuan [2] - The company's net profit for the same period was 4.276 million yuan, ranking 70th, again far below the industry leaders [2] - The main business segments include technical services and development (50.83% of revenue) and information solutions (47.01%) [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 33.24%, lower than the industry average of 38.93% [3] - The gross profit margin was 29.44%, slightly below the industry average of 29.96% but improved from 27.61% in the previous year [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 16.28% to 48,900, while the average number of shares held per shareholder increased by 19.34% [5] - Notable changes among the top ten shareholders include an increase in holdings by Hong Kong Central Clearing Limited and the entry of new shareholders [5] Business Development - In the first half of 2025, the company experienced a decline in total revenue and net profit, but new contract signings surged by 282.6% to 677 million yuan, indicating a strong order backlog [6] - Significant growth was noted in the tobacco and oil & gas sectors, with revenue increases of 35.56% and 95.85%, respectively [6] - The company is increasing its investment in AI research, achieving progress in advanced fields such as AI anesthesia robots [6]

Core Insights - The company reported a total revenue of 194 million yuan for Q3 2025, ranking 85th among peers, which is a decrease of 24.49 million yuan or 11.22% year-on-year [1] - The net profit attributable to shareholders was 4.51 million yuan, ranking 57th among peers, reflecting a decline of 1.68 million yuan or 27.07% year-on-year [1] - The net cash flow from operating activities was -48.67 million yuan, ranking 61st among peers, with an increase of 54.14 million yuan compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 33.24%, ranking 51st among peers, which is an increase of 7.35 percentage points from the previous quarter and 16.05 percentage points from the same period last year [3] - The latest gross profit margin is 29.44%, ranking 49th among peers, with a slight decrease of 0.03 percentage points from the previous quarter but an increase of 1.83 percentage points year-on-year [3] - The latest return on equity (ROE) is 0.53%, ranking 59th among peers, which is a decrease of 0.19 percentage points from the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.02 yuan, ranking 54th among peers, which is a decrease of 0.01 yuan or 27.27% year-on-year [3] - The total asset turnover ratio is 0.16 times, ranking 86th among peers, reflecting a decrease of 0.03 times or 17.35% year-on-year [3] - The inventory turnover ratio is 0.90 times, ranking 93rd among peers, which is a decrease of 0.14 times or 13.83% year-on-year [3] Shareholder Information - The number of shareholders is 48,900, with the top ten shareholders holding 110 million shares, accounting for 37.17% of the total share capital [3] - The largest shareholder is the Chinese Academy of Sciences Holdings Co., Ltd., holding 30.5 million shares [3]

Group 1 - The core point of the article is that Zhongke Information (SZ 300678) held its 24th meeting of the fourth board of directors on October 29, 2025, to review the proposal regarding the implementation details of total wage management [1] - For the first half of 2025, Zhongke Information's revenue composition is as follows: tobacco accounts for 33.9%, on-site meetings for 22.96%, others for 21.09%, government for 12.51%, and oil for 9.55% [1] - As of the report, Zhongke Information has a market capitalization of 9.9 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥52,196,387.10, a decrease of 21.71% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2025 was ¥745,806.94, down 37.86% year-on-year[4] - The basic earnings per share for Q3 2025 was ¥0.0025, reflecting a decline of 37.50% compared to the previous year[4] - Total operating revenue for the current period was ¥193,751,244.66, a decrease of 11.2% from ¥218,236,369.58 in the previous period[22] - Operating profit for the current period was ¥9,328,859.36, compared to ¥10,778,282.84 in the previous period, indicating a decline of 13.5%[22] - Net profit for the current period is 4,275,958.81, a decrease of 16.1% from 5,093,497.45 in the previous period[23] - Total comprehensive income for the current period is 4,275,958.81, a decrease of 16.1% from 5,093,497.45 in the previous period[23] - Basic and diluted earnings per share are both 0.0152, down from 0.0209 in the previous period[23] Assets and Liabilities - Total assets at the end of Q3 2025 reached ¥1,272,048,615.06, an increase of 6.64% from the end of the previous year[5] - The total assets increased to ¥1,272,048,615.06 from ¥1,192,790,641.91, representing a growth of 6.7%[21] - Current liabilities rose to ¥414,139,773.43, up from ¥321,279,947.23, marking an increase of 29%[21] - The total liabilities increased to ¥422,816,346.41 from ¥333,015,017.42, reflecting a growth of 27%[21] - The total equity attributable to shareholders decreased to ¥846,218,671.64 from ¥856,524,656.94, a decline of 1.9%[21] - Cash and cash equivalents decreased to ¥398,521,682.34 from ¥476,092,459.93, a reduction of 16.3%[20] Cash Flow - The company's net cash flow from operating activities showed a negative net amount of ¥48,672,019.52, an increase of 52.66% in outflow compared to the previous year[4] - Operating cash flow net amount is -48,672,019.52, an improvement from -102,812,910.72 in the previous period[26] - Investment activities generated a net cash flow of -4,008,444.66, compared to -75,727,937.82 in the previous period, indicating a significant reduction in cash outflow[26] - Cash flow from financing activities resulted in a net outflow of -24,541,484.15, compared to -2,701,147.46 in the previous period[27] - Cash and cash equivalents at the end of the period stand at 390,462,665.57, an increase from 310,737,485.51 in the previous period[27] Inventory and Prepayments - The company reported a significant increase in inventory, which rose by 131.66% to ¥212,030,334.74 due to increased costs of unfinished projects[9] - The company experienced a substantial increase in prepayments, which rose by 228.36% to ¥125,121,747.97, attributed to project progress[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,947[13] - The largest shareholder, China Academy of Sciences Holdings Co., Ltd., holds 90,477,651 shares, representing a significant portion of the company's equity[15] - The total number of shares held by the top 10 unrestricted shareholders amounts to 100,000,000 shares, indicating strong institutional support[15] - The company has a total of 10,837,361 restricted shares at the beginning of the period, with 5,729,463 shares released from restriction during the period[17] - The company plans to release 268,880 additional restricted shares, resulting in a total of 5,376,778 restricted shares remaining[17] - The company has not disclosed any significant changes in shareholder relationships among the top 10 shareholders[15] - The company has a total of 1,339,400 shares held by Jiangsu Bank Co., Ltd. under a flexible allocation mixed securities investment fund[15] - The company has a total of 1,872,900 shares held by Wu Zhiming, indicating individual investor interest[15] - The company has a total of 1,367,400 shares held by China Minsheng Bank Co., Ltd., reflecting institutional investment[15] - The company has a total of 1,359,950 shares held by Qianhai Life Insurance Co., Ltd., showcasing diversified investment sources[15] - The company has a total of 2,169,828 shares held by Shanghai Tongli Industrial Co., Ltd., indicating potential strategic partnerships[15] Other Income - The company reported a decrease in other income by 44.64% to ¥1,475,072.24, due to reduced government subsidies recognized during the reporting period[12] - The company reported an investment income of ¥12,002,006.20, up from ¥6,612,362.94, indicating an increase of 81.5%[22]

中科院成都信息技术股份有限公司2025年第三季度报告全文于 2025年10月30日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请投资者查阅。 特此公告。 中科院成都信息技术股份有限公司 董事会 证券代码：300678 证券简称：中科信息 公告编号：2025-078 中科院成都信息技术股份有限公司 2025年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2025 年 10 月 29 日 1 / 1 ...